Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone

Haematologia

Volumn 32, Issue 1, 2002, Pages 49-57

  Bolaman, Zahit ^a   Köseoǧlu, Mehmet ^b   Ayyildiz, Orhan ^c   Kadiköylü, Gürhan ^a   Sönmez, Hulki Meltem ^a   Demir, Süleyman ^b   Müftuüoǧlu, Ekrem ^c  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

^c DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Blastic phase; Chronic myelogenous leukemia; High dose methylprednisolone

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AZACITIDINE; CARBOPLATIN; CLADRIBINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; MEPREDNISONE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BACTEREMIA; BLAST CELL CRISIS; BONE MARROW HYPOPLASIA; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUSHING; HUMAN; LEUKEMIA REMISSION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; PHILADELPHIA 1 CHROMOSOME; PNEUMONIA; PROGNOSIS; RASH; STREPTOCOCCUS INFECTION; SURVIVAL TIME; VALIDATION PROCESS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036901814     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: 10.1163/156855902760262763     Document Type: Article

References (31)

1. Canellos, G. P., Chronic granulocytic leukemia, Med. Clin. North. Amer. 60, 1001-1008 (1976).
2. Allen, S. L., Coleman, M., Terminal-phase chronic myelogenous leukemia: Approach to treatment, Cancer Invest. 3, 491-503 (1985).
3. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., Kantarjian, H., The biology of chronic meyeloid leukemia, N. Engl. J. Med. 341, 164-172 (1999).
4. Kantarjian, H., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., Mc Credie, K. B., Freireich, E. J., Characteristics of accelereted disease in chronic myelogenous leukemia, Cancer 61, 1441-1446 (1988).
5. Kantarjian, H., Walters, R. S., Keating, M. J., Talpaz, M., Andersson, B., Beran, M., Mc Credie, K. B., Freireich, E. J., Treatment of blastic phase of chronic myelogenous leukemia with mitoxantrone and high dose cytosine arabinoside, Cancer 62, 672-676 (1988).
6. Hoelzer, D., Treatment of acute lymphoblastic leukemia, Semin. Hematol. 31, 1-15 (1944).
7. Lowenberg, B., Suciu, S., Achimbaud, E., Haak, H., de Cataldo, R., Dekker, A. W., Berneman, Z. N., Thyss, A., van der Lelie, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemeijer, A., Solbu, G., Zittoun, G., Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group, Clin. Oncol. 16, 872-881 (1988).
8. Bucher, T., Hiddeman, W., Treatment strategies in acute myeloblastic leukemia. A first line treatment, Blut 60, 61-67 (1990).
9. Brito-babapulle, Catovsky, D., Slocombe, G., Newland, A. C., Marcus, R. E., Goldman, J. M., Galton, D. A., Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia, Cancer Treat. Rep. 71, 161-163 (1987).
10. McCullum, P. K., Rohatiner, A. Z., Davis, C. L., Whelan, J. S., Oza, A. M., Lim, J., Love, S., Amess, J. A., Leahym Gupta, R. K., Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients, Ann. Hematol. 711, 35-39 (1995).
11. Hicsonmez, G., Ozsoylu, S., Tuncer, A. M., Differentiation of myeloid leukemic cells induced by high-dose methylprednisolone in patients with acute myeloblastic leukemia and its therapeutic potential, Leuk. Res. 15, 537-541 (1991).
12. Ozbek, N., Erdemli, E., Hicsonmez, G., Okur, H., Tekelioglu, M., Effect of methylprednisolone on human myloid leukemic cells in vitro, Am. J. Haematol. 60, 255-259 (1999).
13. Yetgin, S., Gurgey, A., Tuncer, A. M., Gumruk, F., Yenicesu, I., A comparison of the effect of high dose methylprednisolone in acute lymphoblastic leukemia patients with randomization, Leuk. Res. 22, 485-493 (1998).
14. Bolaman, Z., Bilgir, O., Ertop, S., Yenice, N., Yilmaz, M., Muftuoglu, E., Treatment of blastic phase chronic myeloid leukemia with megadose methyprednisolone, J. Chemotherapy 1 (Suppl.), 670-671 (1993).
15. Pacuicci, P. A., Kaeveney, C., Cuttner, J., Holland, J. F., Mitoxantrone, vincristine and prednisone in adults with relapsed or primarily refractory acute lymphoblastic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myeloid leukemia, Cancer Res. 1, 5234-5237 (1987).
16. Geller, R. B., Zahurak, M., Hurwitz, C. A., Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: The significance of the stem-cell glycoprotein CD 34(MY 10), Br. J. Hematol. 76, 340-347 (1990).
17. Trujillo, J. M., Cork, A., Ahearn, M. J., Younes, E. L., McCredie, K. B., Hematologic and cytologic characterization of 8:21 translocation acute granulocytic leukemia, Blood 53, 659-706 (1979).
18. Keating, M. J., Smith, T. L., Gehan, E. A., McCredie, K. B., Bodey, G. P, Freireich, E. J., A prognostic factor analysisis for use in the development of predictive models for response in adult leukemia, Cancer 50, 457-465 (1982).
19. Sacchi, S., Kantajian, H. M., O'Brien, S., Cortes, J., Rios, M. B., Giles, F. J., Beran, M., Keller, C. A., Keating, M. J., Talpaz, M., Chronic myeloid leukemai in nonlympoid blastic phase: analysis of results of the first salvage therapy with three different treatment approach for 162 patients, Cancer 15, 2632-2641 (1999).
20. Dutcher, J. P., Lee, S., Paietta, E., Stewart, J. A., Wiernik, P. H., Phase II study of carboplatin in blast crisis of the chronic myeloid leukemia; Eastern Cooperative Oncology Group Study E 1992, Leukemia 12, 1037-1040 (1998).
21. Iacobani, S. J., Plunkett, W., Kantarjian, H. M., Astey, E., Keating, M. J., McCredie, K. B., Freireich, E. J., High dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis, J. Clin. Oncol. 4, 1079-1088 (1986).
22. Wilhelm, M., O'Brien, S., Rios, M. B., Estey, K., Keating, M. J., Plunkett, W., Serenson, M., Kantarjian, H. M., Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase, Leuk. Lymphoma 34, 511-518 (1999).
23. Dann, E. J., Anastasi, J., Larson, R. A., High dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blastic phase, J Clin. Oncol. 16, 1498-1504 (1988).
24. Jehn, U., Heinemann, V, Succesful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-doseinterferon alpha combined with hydroxyurea, Cancer Detect. Prev. 22, 258-264 (1998).
25. Montefusco, E., Petti, M. C., Alimena, G., Latagliata, R., Celesti, F., Captria, S., Amadori, S., Arristo, G., Mandelli, F., Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia, Ann. Oncol. 8, 175-179 (1997).
26. Bauduer, F., Delmer, A., Blanc, M. C., Delmas-Marialet, B., Cadion, M., Rio, B., Marie, J. B., Zittoun, R., Treatment of chronic myelogenous leukemia in blastic crisis and in accelereted phase with high or intermediate dose cytosine arabinoside and amsacrine, Leuk. Lymphoma 10, 195-200 (1993).
27. Abdulkadyrov, K. M., Bessmel'tzev, S. S., Rukavitzyn, O. A., Shilova, E. R., Sheherbakova, E. G., Effectiveness of various chemotherapy regimen for patients with chronic myeloid leukemiain blast crisis, Vopr Onkol. 43, 284-289 (1997).
28. Tedeschi, A., Montillo, M., Ferrara, Nosari, A., Mele, G., Copra, C., Leoni, P., Morra, E., Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG), Eur. J. Haematol. 64, 182-187 (2000).
29. Mauro, M. J., O'Dwyer, M. E., Druker, B. J., STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy, Cancer Chemother. Pharmacol. 48 (Suppl. 1), S77-S78 (2001).
30. Verweij, J., Judson, I., van Oosterom, A., STI571: a magic bullet?, Eur. J. Cancer 37, 1816-1819 (2001).
31. Gambacorti-Passerini, C., Barni, R., Marchesi, E., Verga, M., Rossi, F., Rossi, F., Pioltelli, P., Pogliani, E., Corneo, G. M., Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease, Brit. J. Haematol. 112, 972-974 (2001).